{"product_id":"anti-human-il-17a-hil-17a-monoclonal-antibody","title":"Anti Human IL-17A (hIL-17A) Monoclonal Antibody","description":"\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAnti Human IL-17A (hIL-17A) Monoclonal Antibody \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClone HI401    Catalog#: A50401\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e: \u003cspan\u003eIL17 is secreted by CD4 T cells and can induce the synthesis and secretion of IL-6, IL-8, G-CSF, and PGE2 in epithelial cells, endothelial cells, and fibroblasts, promoting the expression of ICAM-1. IL-17 is an early activator of T cell-induced inflammatory responses and can amplify inflammation by promoting the release of pro-inflammatory cytokines. After binding to its receptor, IL-17 can exert its biological effects through the MAP kinase pathway and the nuclear factor kB (nuclear factor kB, NF-kB) pathway. Th17 cells can produce IL-17A, IL-17F, IL-6, and tumor necrosis factor alpha (tumor necrosis factor alpha, TNF-a), which can collectively mobilize and activate neutrophils. The IL-17 produced by Th17 cells can effectively mediate the activation process of neutrophil recruitment, thereby effectively mediating tissue inflammation. Therefore, IL-17 plays a key role in autoimmune diseases and tumor development, making it a target molecule for drug design.\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eIsotype:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eMouse IgG\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eSpecies reactivity:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eMouse\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eProduction:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eTissue culture\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003ePurification:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eProtein G\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eRecommended Isotype Control:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eMouse IgG1 Isotype control\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eApplications:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eIn vivo IL-17A neutralization\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eImmunogen: \u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eE. coli expressed recombinant \u003cspan data-mce-fragment=\"1\"\u003ehIL-17 \u003c\/span\u003eprotein\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eStorage: \u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eStore at +4°C short term (1-2 weeks). Store at -20°C long term.\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eFormulation:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003ePBS, pH 7.4, Filter sterilized. Endotoxin level tests less than 0.06 EU\/ug.\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eClonality:\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"387\"\u003e\n\u003cp\u003eMonoclonal\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eReference:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eJarocki M, Karska J, et al. (2022). Interleukin 17 and Its Involvement in Renal Cell Carcinoma.J Clin Med. 2022 Aug 24;11(17):4973.\u003c\/li\u003e\n\u003cli\u003eNorden A, Oulee A, et al.(2022). Anti-drug antibodies of IL-17 inhibitors forpsoriasis: a systematic review.J Dermatolog Treat. Aug 31:1-6.\u003c\/li\u003e\n\u003cli\u003eRitzmann F, Lunding LP, et al.(2022).IL-17 Cytokines and Chronic Lung Diseases.Cells.Jul 6;11(14):2132.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eIntended for research use only. Not for human, therapeutic, or diagnostic applications.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Humimmu LLC.  \u003c\/p\u003e","brand":"Humimmu","offers":[{"title":"100μg","offer_id":47252371734823,"sku":"A50401-100ug","price":699.0,"currency_code":"USD","in_stock":true},{"title":"500μg","offer_id":47252371767591,"sku":"A50401-500ug","price":1999.0,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":47252371800359,"sku":"A50401-1mg","price":2999.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0735\/6481\/5655\/files\/AntihIL-17A.png?v=1702003268","url":"https:\/\/www.humimmu.com\/products\/anti-human-il-17a-hil-17a-monoclonal-antibody","provider":"Humimmu","version":"1.0","type":"link"}